551 related articles for article (PubMed ID: 16424063)
1. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
Bettuzzi S; Brausi M; Rizzi F; Castagnetti G; Peracchia G; Corti A
Cancer Res; 2006 Jan; 66(2):1234-40. PubMed ID: 16424063
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view.
Bettuzzi S; Rizzi F; Belloni L
Pol J Vet Sci; 2007; 10(1):57-60. PubMed ID: 17388027
[TBL] [Abstract][Full Text] [Related]
3. Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial.
Micali S; Territo A; Pirola GM; Ferrari N; Sighinolfi MC; Martorana E; Navarra M; Bianchi G
Arch Ital Urol Androl; 2017 Oct; 89(3):197-202. PubMed ID: 28969404
[TBL] [Abstract][Full Text] [Related]
4. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
6. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial.
Price D; Stein B; Sieber P; Tutrone R; Bailen J; Goluboff E; Burzon D; Bostwick D; Steiner M
J Urol; 2006 Sep; 176(3):965-70; discussion 970-1. PubMed ID: 16890670
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
9. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
10. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
11. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
12. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
13. Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer.
Meyer F; Têtu B; Bairati I; Lacombe L; Fradet Y
Can J Urol; 2006 Oct; 13(5):3255-60. PubMed ID: 17076947
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
15. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
16. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
17. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
18. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study.
Noguchi M; Kakuma T; Tomiyasu K; Kurita Y; Kukihara H; Konishi F; Kumamoto S; Shimizu K; Kondo R; Matsuoka K
Asian J Androl; 2008 Jul; 10(4):651-8. PubMed ID: 18097503
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer chemoprevention by green tea.
Gupta S; Ahmad N; Mukhtar H
Semin Urol Oncol; 1999 May; 17(2):70-6. PubMed ID: 10332919
[TBL] [Abstract][Full Text] [Related]
20. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
